A single-center study at the University Medical Center of Astana, Kazakhstan, demonstrated the effectiveness of the Aeson® total artificial heart in treating three heart failure patients with pulmonary hypertension (PHT). The device’s ability to estimate transpulmonic resistance in real time allowed physicians to monitor PHT, a condition that often disqualifies patients from heart transplants. Following implantation, all three patients showed improved functional capacity and ultimately received successful heart transplants.
This study is important because a significant portion of advanced heart failure patients also suffer from PHT, limiting their treatment options. Existing treatments like left ventricular assist devices (LVADs) can carry the risk of right heart failure with prolonged use. The Aeson® device, with its biventricular support and real-time monitoring capabilities, presents a potential solution for these patients, either as a bridge to transplant or possibly as a permanent therapy.
The Aeson® device allowed for real-time monitoring of transpulmonic resistance, which was crucial in assessing the patients’ readiness for transplant. After receiving the implant, the patients’ functional capacity improved, and their PHT indicators eventually fell within acceptable ranges for transplantation. All three patients were successfully discharged from the hospital within two months of the implant procedure and subsequently received heart transplants within a year.
This study’s publication suggests a promising future for the Aeson® total artificial heart in managing complex cases of heart failure complicated by PHT. Larger studies are needed to validate these findings, but the initial results indicate this technology could significantly improve outcomes for a large group of patients currently facing limited therapeutic options. This could lead to a paradigm shift in the treatment of advanced heart failure with PHT, potentially expanding transplant eligibility and improving long-term survival.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
